$-0.01
(Market cap
$5 Mln
Recently Viewed
Clear AllMarket cap
$5 Mln
Revenue (TTM)
$36 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
24.41
EV/EBITDA
-7.7
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,905,945
CFO
$-19.78 Mln
EBITDA
$-25.13 Mln
Net Profit
$-56.66 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sunshine Biopharma (SBFM)
| -19.2 | -1.6 | -19.8 | -34.2 | -57.1 | -71.8 | -61.6 |
|
BSE Sensex
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Sunshine Biopharma (SBFM)
| -59.0 | -44.6 | -57.5 | 345.9 | 96.3 | -97.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sunshine Biopharma (SBFM)
|
1.0 | 4.9 | 36.0 | -6.9 | -12.9 | -29.4 | -- | 0.2 |
| 12.8 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 0.6 | 23.9 | 4.2 | -3.6 | -55.0 | -0 | -- | 1.2 | |
| 0.4 | 19.3 | 71.3 | -28.5 | -22.3 | -137 | -- | 1.0 | |
| 3.1 | 1,118.8 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.2 | |
| 8.1 | 5,499.1 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.7 | 1.1 | |
| 226.6 | 555,224.5 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 26.7 | 6.8 | |
| 0.1 | 126.5 | 0.0 | -17.4 | -- | -- | -- | 18.1 | |
| 46.4 | 112,077.9 | 47,354.0 | 7,555.0 | 19.6 | 10.3 | 20.2 | 1.3 |
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through... Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida. Read more
CFO & Secretary
Mr. Camille Sebaaly
CFO & Secretary
Mr. Camille Sebaaly
Headquarters
Fort Lauderdale, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sunshine Biopharma Inc (SBFM) is $0.99 (NASDAQ) as of 27-Apr-2026 10:29 EDT. Sunshine Biopharma Inc (SBFM) has given a return of -57.14% in the last 3 years.
Since, TTM earnings of Sunshine Biopharma Inc (SBFM) is negative, P/E ratio is not available.
The P/B ratio of Sunshine Biopharma Inc (SBFM) is 0.21 times as on 24-Apr-2026, a 96 discount to its peers’ median range of 5.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.82
|
0.21
|
|
2024
|
-0.58
|
0.13
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Sunshine Biopharma Inc (SBFM) are Rs 2.43 and Rs 0.95 as of 27-Apr-2026.
Sunshine Biopharma Inc (SBFM) has a market capitalisation of $ 5 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sunshine Biopharma Inc (SBFM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.